Score Overview
Explore the 2021 public Archive ranking →
Where Genmab AS has ranked, year by year
Showing 1 year ranking history by HDB Score.
Top 50 on HDB Score for 1 year, since 2021, through 2021.
- GMAB
2014: 9.2% · 2021: 1.3% · free through 2021 · longest runs
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-09-29 | $ 35.57 | — |
1 Year2025-09-29 | $ 29.33 | 21.28% |
5 Years2021-09-29 | $ 42.34 | -15.99% |
10 Years2016-09-29 | $ 16.80 | 111.75% |
All Time2009-06-01 | $ 3.77 | 9x |
| Period | Last Price2026-09-29 | 1 Year2025-09-29 | 5 Years2021-09-29 | 10 Years2016-09-29 | All Time2009-06-01 |
|---|---|---|---|---|---|
| Price | $ 35.57 | $ 29.33 | $ 42.34 | $ 16.80 | $ 3.77 |
| Return | — | 21.28% | -15.99% | 111.75% | 9x |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
Reported in DKK
| Year | |||
|---|---|---|---|
| TTM | kr 4.13B | kr 788M | kr 1.50B |
| 2025 | kr 3.72B | kr 963M | kr 1.71B |
| 2024 | kr 21.52B | kr 7.84B | kr 21.10B |
| 2023 | kr 16.47B | kr 4.35B | kr 28.13B |
| 2022 | kr 14.50B | kr 5.45B | kr 22.32B |
| 2021 | kr 8.41B | kr 2.95B | kr 19.33B |
| 2020 | kr 10.11B | kr 4.75B | kr 16.07B |
| 2019 | kr 5.36B | kr 2.16B | kr 10.97B |
| 2018 | kr 3.02B | kr 1.47B | kr 6.10B |
| 2017 | kr 2.36B | kr 1.10B | kr 5.42B |
| 2016 | kr 1.81B | kr 1.18B | kr 3.92B |
| 2015 | kr 1.13B | kr 763M | kr 3.49B |
| 2014 | kr 850M | kr 301M | kr 2.66B |
| 2013 | kr 663M | kr 112M | kr 1.55B |
| 2012 | kr 484M | -kr 487M | kr 1.50B |
| 2011 | kr 350M | -kr 596M | kr 1.10B |
| 2010 | kr 582M | -kr 321M | kr 1.64B |
| IPO2009 | kr 586M | -kr 1.01B | kr 1.27B |
Genmab AS fundamental performance
Between 2020 and 2025, revenue declined from kr 10.11B to kr 3.72B and net income declined from kr 4.75B to kr 963M. Revenue increased in 4 of those 5 years; net income in 2.
Across Genmab AS's full reported history, from 2009 to 2025, revenue grew from kr 586M to kr 3.72B and net income went from -kr 1.01B to kr 963M. Revenue increased in 76% of the years measured; net income in 65%.
Genmab AS currently holds a 5-year HDB Score of 4.4 out of 10. How the HDB Score is calculated.
Membership
Continue GMAB’s history
The public Archive runs through 2021. Membership adds recent and current rankings.
- Recent and current rankings across 3,814 companies
- Compare companies with the latest data
- Track your research shortlist in a portfolio
